Semi-Annual Report — FY2026 H1
What SanBio Company Limited reported for the period from 2026-02-01 to 2027-01-31.
Filed 2026-09-14View the original on EDINET
How much it says
33Thin
What moved here
7named for the first time
Its own wording
18terms
Which filing this is
38/ 38newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, the company recorded an operating loss of ¥1,909 million, primarily due to expenses related to approval for a partial change to ACUGO's marketing authorization. Foreign exchange gains of ¥185 million also contributed to an ordinary loss of ¥1,730 million. Cash and cash equivalents stood at ¥12,677 million at period-end, down from the end of the previous consolidated fiscal year.
Komori's summary of this document, not the document's own words.33Thin
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
61
Detailed
14
Almost nothing
60
Detailed
50
Typical
15
Almost nothing
41
Thin
27
Almost nothing
7
Almost nothing
35
Thin
10
Almost nothing
R&D spend12億円Money spent making new things.
Cash left over-21億円Cash from the business, less what went into equipment.
Spent on equipment1億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.